Abbott Laboratories

Abbott received FDA authorization for the Libre Duo, the first prescription 2‑in‑1 continuous glucose monitor that also measures beta‑hydroxybutyrate ketone levels and worn for 10 days. The device sends glucose and ketone alerts via the existing app and smartwatch integrations, aiming to help detect diabetic ketoacidosis early—especially in children, insulin pump users, and patients on SGLT2 inhibitors. Clinicians praise the potential but caution about accuracy, interpretation, and false positives; Abbott says it set ketone performance standards with the FDA and currently plans prescription‑only distribution. The sensor could expand metabolic monitoring and later reach wider consumer markets, but initial adoption may face data‑fatigue and wearable‑hype challenges. » Altro su theverge.com

Abbott has received CE approval for the Amulet 360 occluder to close the left atrial appendage; the implant is intended for patients with non-valvular atrial fibrillation who cannot receive long-term anticoagulation. First procedures were performed at clinics in Frankfurt, Lübeck and Aarhus, and availability will be expanded to other European countries in the coming weeks. The approval is based on the VERITAS study with 400 patients, which showed a successful implantation rate of 99.8% at 45 days and complete closure without leaks >3 mm in 93.9%. In the US the Amulet 360 is currently approved only for investigational use; this is Abbott’s fourth major electrophysiology approval in just over a year. » Altro su de.investing.com

The FDA granted Abbott de novo authorization for the Libre Duo 10 Day system, which continuously measures glucose and ketone levels and is designed to warn of elevated ketones. The device meets both the standard for integrated continuous glucose monitoring and the new standard for integrated glucose and ketone monitoring and has been designated a Breakthrough Device. Libre Duo 10 Day is intended for people with type 1 and type 2 diabetes from two years of age, offers a wear time of up to 10 days, and is expected to launch in the US later this year; Abbott plans integrations with several automated insulin delivery systems. » Altro su de.investing.com